BUY Lupin Limited — Dharmesh Kant, Cholamandalam Securities
byDharmesh Kant, Cholamandalam SecuritiesHorizon: 1 year3 Jul 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Lupin receives US FDA approval for Modafinil 100 mg, 200 mg tablets
NewsCnbc-Tv18·4 Sept · 3d ago
Lupin Ltd has received approval from the U.S. FDA for its Modafinil Tablets, USP.
BSE · Company Update·4 Sept · 3d ago
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·4 Sept · 3d ago
1 advisor has an active short-term BUY call on this stock, issued in the last 14 days
Advisor consensus · adjacent horizon·28 Aug · 1w ago
8 other SEBI-registered advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days
Advisor consensus · same horizon·27 Aug · 2w ago
Lupin share falls 2%; Citi downgrades to Sell, cuts target price to Rs 2,050
NewsEt-Markets·27 Aug · 2w ago
Lupin share price: Citi downgrades, cuts target; Bernstein sees Kalydeco ruling as key positive
NewsCnbc-Tv18·27 Aug · 2w ago
1 other SEBI-registered advisor has an active long-term SELL call on this stock, issued in the last 14 days
Advisor consensus · same horizon·27 Aug · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.